Skip to main
MRK

Merck (MRK) Stock Forecast & Price Target

Merck (MRK) Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 22%
Buy 39%
Hold 39%
Sell 0%
Strong Sell 0%

Bulls say

Merck & Co is a global pharmaceutical company with a diverse portfolio of products across various therapeutic areas. With its immuno-oncology platform, led by Keytruda, and a strong focus on innovation and research and development, Merck is well-positioned to capture a significant share of the growing pharmaceutical market. The recent acquisitions of Cidara Therapeutics and its promising drug candidate CD388, as well as the positive topline results from the Phase 2 CADENCE study for Winrevair, indicate potential for further growth and success. Additionally, Merck's comprehensive diversity and sustainability programs reflect its commitment to long-term and sustainable business operations.

Bears say

Merck & Co is facing multiple headwinds with their flagship drug Keytruda, including potential competition and patent expiration, which is causing concern for the company's long-term earnings growth. However, their recent data on Winrevair for Gr2 PH show promising results and potential for significant growth in this market. The stock is currently undervalued and has the potential for further re-rating as the market recognizes Merck's ability to offset Keytruda's decline with their current products and pipeline. However, the company still faces risks in their clinical trials, which could affect their future growth potential.

Merck (MRK) has been analyzed by 18 analysts, with a consensus rating of Buy. 22% of analysts recommend a Strong Buy, 39% recommend Buy, 39% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Merck and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Merck (MRK) Forecast

Analysts have given Merck (MRK) a Buy based on their latest research and market trends.

According to 18 analysts, Merck (MRK) has a Buy consensus rating as of Jun 2, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $125, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $125, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Merck (MRK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.